148 related articles for article (PubMed ID: 37709536)
21. Improving the Diagnostic Performance of
Swart LE; Gomes A; Scholtens AM; Sinha B; Tanis W; Lam MGEH; van der Vlugt MJ; Streukens SAF; Aarntzen EHJG; Bucerius J; van Assen S; Bleeker-Rovers CP; van Geel PP; Krestin GP; van Melle JP; Roos-Hesselink JW; Slart RHJA; Glaudemans AWJM; Budde RPJ
Circulation; 2018 Oct; 138(14):1412-1427. PubMed ID: 30018167
[TBL] [Abstract][Full Text] [Related]
22. The impact of
Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
[TBL] [Abstract][Full Text] [Related]
23. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
24. Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from
Schmidkonz C; Krumbholz M; Atzinger A; Cordes M; Goetz TI; Prante O; Ritt P; Schaefer C; Agaimy A; Hartmann W; Rössig C; Fröhlich B; Bäuerle T; Dirksen U; Kuwert T; Metzler M
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1564-1575. PubMed ID: 31853559
[TBL] [Abstract][Full Text] [Related]
25. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
26. Prone position PET/CT is useful in reducing gravity-dependent opacity-related [
Song YH; Moon JW; Kim YN; Woo JY; Son HJ; Lee SH
Eur Radiol; 2023 Nov; 33(11):8270-8278. PubMed ID: 37322163
[TBL] [Abstract][Full Text] [Related]
27. The role of 18F-FDG PET and PET/CT in the evaluation of primary cutaneous lymphoma.
Qiu L; Tu G; Li J; Chen Y
Nucl Med Commun; 2017 Feb; 38(2):106-116. PubMed ID: 27792043
[TBL] [Abstract][Full Text] [Related]
28. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
[TBL] [Abstract][Full Text] [Related]
29. Lack of clinical impact of
Liu J; Larcos G; Howle J; Veness M
Australas J Dermatol; 2017 May; 58(2):99-105. PubMed ID: 26459330
[TBL] [Abstract][Full Text] [Related]
30. Fluorodeoxyglucose positron emission tomography (18F-FDG PET)-computed tomography (CT) in the initial staging of bladder cancer: a single institution experience.
Shahait M; Abu-Hijlih R; Farkouh A; Obeidat S; Salah S; Abdlkadir AS; Al-Ibraheem A
J Egypt Natl Canc Inst; 2023 Jul; 35(1):21. PubMed ID: 37455263
[TBL] [Abstract][Full Text] [Related]
31.
Albano D; Treglia G; Gazzilli M; Cerudelli E; Giubbini R; Bertagna F
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):422-430. PubMed ID: 32169480
[TBL] [Abstract][Full Text] [Related]
32. Artificial Intelligence in Breast Cancer: A Systematic Review on PET Imaging Clinical Applications.
Alongi P; Rovera G; Stracuzzi F; Popescu CE; Minutoli F; Arnone G; Baldari S; Deandreis D; Caobelli F
Curr Med Imaging; 2023; 19(8):832-843. PubMed ID: 36703586
[TBL] [Abstract][Full Text] [Related]
33. Thoracic staging with
Schaarschmidt BM; Grueneisen J; Metzenmacher M; Gomez B; Gauler T; Roesel C; Heusch P; Ruhlmann V; Umutlu L; Antoch G; Buchbender C
Eur Radiol; 2017 Feb; 27(2):681-688. PubMed ID: 27180186
[TBL] [Abstract][Full Text] [Related]
34.
Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
Verghote F; Poppe L; Verbeke S; Dirix P; Albersen M; De Meerleer G; Berghen C; Ost P; Villeirs G; De Visschere P; De Man K; De Maeseneer D; Rottey S; Van Praet C; Decaestecker K; Fonteyne V
BMC Cancer; 2021 Oct; 21(1):1113. PubMed ID: 34663254
[TBL] [Abstract][Full Text] [Related]
36. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
[TBL] [Abstract][Full Text] [Related]
37. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
38. Comparison of
Kaste SC; Snyder SE; Metzger ML; Sandlund JT; Howard SC; Krasin M; Shulkin BL
J Nucl Med; 2017 Mar; 58(3):419-424. PubMed ID: 27609791
[TBL] [Abstract][Full Text] [Related]
39. Accuracy of ChatGPT in head and neck oncological board decisions: preliminary findings.
Lechien JR; Chiesa-Estomba CM; Baudouin R; Hans S
Eur Arch Otorhinolaryngol; 2024 Apr; 281(4):2105-2114. PubMed ID: 37991498
[TBL] [Abstract][Full Text] [Related]
40. Incidence of Brain Metastases on Follow-up
Nia ES; Garland LL; Eshghi N; Nia BB; Avery RJ; Kuo PH
J Nucl Med Technol; 2017 Sep; 45(3):193-197. PubMed ID: 28705927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]